Dutch Nationwide Cohort Experience with a New PROMs Set in Metabolic and Bariatric Surgery: BODY-Q Obesity Module.

Purpose: Patient-reported outcomes are important as obesity is a chronic disease with a substantial impact. A multidisciplinary task force selected six scales (48 questions) from the validated BODY-Q questionnaire. This subset was gradually introduced and evaluated in a mandatory nationwide registry.

Acute pilonidal abscess: Prospective nationwide audit in the Netherlands.

Aim: The aim of this study was to assess Dutch surgical practice and outcomes for acute pilonidal abscess.

Method: Patients with pilonidal sinus disease (PSD) who underwent surgical treatment between 1 March 2020 and 1 March 2021 at 36 participating hospitals were included in a prospective observational cohort study. For the present study, only patients with an acute abscess were included for analysis.

A nationwide snapshot study on outcomes one year after surgery for chronic pilonidal sinus disease.

Aim: Managing pilonidal sinus disease (PSD) remains challenging due to high recurrence rates and morbidity associated with treatment. The aim of this study was to evaluate the outcomes one year after surgical treatment for chronic PSD in the Netherlands.

Method: Patients with PSD who underwent surgical treatment between March 1, 2020, and March 1, 2021, at 36 participating hospitals were included in a prospective observational cohort study.

[Fever and a papule after a visit to a South-African Wild Park].

A 39-year old man presented in our emergency room with fever, lymphadenopathy in his right groin and a red papule with a dark center. He was treated with doxycycline and recovered well. Serology showed with seroconversion after a few weeks.

Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer.

Background: The efficacy of PD-1 blocking agents in advanced NSCLC has shown prolonged effectiveness, but only in a minority of patients. Multiple biomarkers have been explored to predict treatment benefit, yet their combined performance remains inadequately examined. In this study, we assessed the combined predictive performance of multiple biomarkers in NSCLC patients treated with nivolumab.